AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21252503 — intervention group
Group type: COMPARATOR
Intervention: Low-flux Hemodialysis (HD)
Number of subjects: 34
Study 21252503 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HF and HD
Number of subjects: 34
Study 19432500 — intervention group
Group type: EXPERIMENTAL
Intervention: TZP-101 single doses (160-600 microg/kg)
Number of subjects: 0
Study 19432500 — intervention group
Group type: EXPERIMENTAL
Intervention: TZP-101 multiple doses (80-600 microg/kg/day)
Number of subjects: 0
Study 19432500 — intervention group
Group type: COMPARATOR
Intervention: TZP-101
Number of subjects: 0
Study 19432500 — intervention group
Group type: EXPERIMENTAL
Intervention: TZP-101 protein binding
Number of subjects: 0
Study 20801260 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal tests (step test and grip strength)
Number of subjects: 183
Study 20801260 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal tests (step test and grip strength) combined with body weight
Number of subjects: 183
Study 16143120 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 100 mg
Number of subjects: 292
Study 16143120 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 200 mg
Number of subjects: 292
Study 16143120 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg
Number of subjects: 292
Study 16143120 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab 400 mg (in patients with baseline C-reactive protein levels of 10 mg/L or greater)
Number of subjects: 292
Study 16143120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 16143120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with baseline C-reactive protein levels of 10 mg/L or greater)
Number of subjects: 292
Study 11865835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 1600 mg daily
Number of subjects: 60
Study 11865835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10206296 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐Fluorouracil (5FU)‐based chemotherapy
Number of subjects: 497
Study 7767666 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 33359
Study 7767666 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 33359
Study 7767666 — intervention group
Group type: EXPERIMENTAL
Intervention: RITA randomization
Number of subjects: 33359
Study 7767666 — intervention group
Group type: COMPARATOR
Intervention: Referral for myocardial revascularization
Number of subjects: 33359
Study 7767666 — intervention group
Group type: COMPARATOR
Intervention: Myocardial revascularization
Number of subjects: 33359
Study 2159990 — intervention group
Group type: EXPERIMENTAL
Intervention: Desciclovir, 250 mg three times a day for 14 days
Number of subjects: 14
Study 2159990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2159990 — intervention group
Group type: EXPERIMENTAL
Intervention: Desciclovir
Number of subjects: 14
Study 374208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral vasoactive and cerebral metabolic active substances
Number of subjects: 60
Study 374208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12925554 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (diuretic)
Number of subjects: 9392
Study 12925554 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (alpha-blocker)
Number of subjects: 9392
Study 28918674 — intervention group
Group type: EXPERIMENTAL
Intervention: 150mg Fruitflow
Number of subjects: 12
Study 27084978 — intervention group
Group type: EXPERIMENTAL
Intervention: USL255 (topiramate extended-release capsules) up to 400 mg/day
Number of subjects: 217
Study 23909985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 7
Study 23909985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day plus pioglitazone 15 mg
Number of subjects: 7
Study 23909985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day plus pioglitazone 30 mg
Number of subjects: 7
Study 23909985 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day plus pioglitazone 45 mg
Number of subjects: 7
Study 23909985 — intervention group
Group type: EXPERIMENTAL
Intervention: All combination-treated groups
Number of subjects: 7
Study 23909985 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 7
Study 22419733 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment during euglycemic-hyperinsulinemic clamp
Number of subjects: 157
Study 22419733 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment during hyperglycemic-hyperinsulinemic clamp
Number of subjects: 157
Study 22419733 — intervention group
Group type: EXPERIMENTAL
Intervention: High glucose and insulin treatment in monocytes
Number of subjects: 157
Study 22419733 — intervention group
Group type: COMPARATOR
Intervention: Comparison of NPRC gene expression in VAT vs SAT
Number of subjects: 157
Study 21287477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% (75 mg) and 10 micrograms sufentanil
Number of subjects: 90
Study 21287477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% (75 mg) and 5 micrograms sufentanil
Number of subjects: 90
Study 21287477 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 5% (75 mg) and 2 ml of normal saline (control group)
Number of subjects: 90
Study 18385198 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus i.v. 25 mg weekly
Number of subjects: 208
Study 18385198 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus i.v. 15 mg weekly plus interferon s.c. 6 MU thrice weekly
Number of subjects: 208
Study 18385198 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa (IFN) s.c. up to 18 MU thrice weekly
Number of subjects: 208
Study 15765388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624
Number of subjects: 77
Study 15765388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius UCC4331
Number of subjects: 77
Study 15765388 — intervention group
Group type: COMPARATOR
Intervention: Placebo (malted milk drink)
Number of subjects: 77
Study 11813224 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-lymphocyte antibody induction therapy
Number of subjects: 628
Study 11813224 — intervention group
Group type: COMPARATOR
Intervention: Group-level analyses
Number of subjects: 628
Study 10028216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 30 mg
Number of subjects: 0
Study 10028216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg
Number of subjects: 0
Study 10028216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8566881 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (LS) regimen
Number of subjects: 20
Study 8566881 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MTC) regimen
Number of subjects: 20
Study 8566881 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (LS) regimen (higher dose on day 8)
Number of subjects: 20
Study 8566881 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (MTC) regimen (higher dose on day 8)
Number of subjects: 20
Study 2147736 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg norgestrel + (Cyclo‐Progynova)
Number of subjects: 49
Study 2147736 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg cyproterone acetate (SH D 461 A)
Number of subjects: 49
Study 2147736 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 49
Study 436602 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprodian with rifampicin
Number of subjects: 80
Study 436602 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid, ethambutol, and rifampicin
Number of subjects: 80
Study 436602 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 31016671 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 5 mg/kg based on lean body weight in morbidly obese individuals
Number of subjects: 0
Study 31016671 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin 5 mg/kg based on total body weight in non-obese individuals
Number of subjects: 0
Study 28752837 — intervention group
Group type: EXPERIMENTAL
Intervention: UK ophthalmologists
Number of subjects: 42
Study 28752837 — intervention group
Group type: EXPERIMENTAL
Intervention: ANZ ophthalmologists
Number of subjects: 42
Study 28752837 — intervention group
Group type: COMPARATOR
Intervention: UK group
Number of subjects: 42
Study 28752837 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study 26285157 — intervention group
Group type: EXPERIMENTAL
Intervention: CenterVue MAIA
Number of subjects: 17
Study 26285157 — intervention group
Group type: COMPARATOR
Intervention: Nidek MP-1
Number of subjects: 17
Study 26285157 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 17
Study 25125679 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 54
Study 25125679 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir
Number of subjects: 54
Study 22761551 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint induced movement therapy (CIMT)
Number of subjects: 0
Study 19562243 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive load training for the quadriceps muscle (50% up to 80% of 1-RM) and proprioception training
Number of subjects: 100
Study 19562243 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment of osteoporosis (control group)
Number of subjects: 100
Study 19562243 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive load training and proprioception training
Number of subjects: 100
Study 18025815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone (D, ‐2,095 +/‐ 659 kJ/day)
Number of subjects: 20
Study 18025815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE, ‐1,420 +/‐ 1,084 kJ/day plus three 60‐min sessions per week at 60% of VO(2)max or ‐5,866 kJ/week)
Number of subjects: 20
Study 18025815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise (DE)
Number of subjects: 20
Study 18025815 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (D)
Number of subjects: 20
Study 18025815 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone (D) and Diet plus exercise (DE)
Number of subjects: 20
Study 16051927 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored diabetes lifestyle intervention delivered by trained community residents
Number of subjects: 151
Study 16051927 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with diabetes in the same health care system)
Number of subjects: 151
Study 11429352 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia combined with general anesthesia
Number of subjects: 23
Study 11429352 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and midazolam anesthesia
Number of subjects: 23
Study 11429352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled anesthesia with isoflurane
Number of subjects: 23
Study 9605995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement support group intervention (10-week, once weekly, 90-min/session)
Number of subjects: 119
Study 9605995 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement support group intervention
Number of subjects: 119
Study 9605995 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control condition
Number of subjects: 119
Study 7993207 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with a 1 microgram/h ganciclovir implant
Number of subjects: 26
Study 7993207 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment
Number of subjects: 26
Study 7993207 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir implant
Number of subjects: 26
Study 2691815 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g.100 ml‐1 glucose (G)
Number of subjects: 0
Study 2691815 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g.100 ml‐1 maltodextrin plus 3 g.100 ml‐1 fructose (MD)
Number of subjects: 0
Study 2691815 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g.100 ml‐1 sucrose (I)
Number of subjects: 0
Study 2691815 — intervention group
Group type: COMPARATOR
Intervention: Artificially sweetened water
Number of subjects: 0
Study 31064966 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk olfactory stimulation provided 12 times over 15 days
Number of subjects: 28
Study 31064966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breast milk olfactory stimulation)
Number of subjects: 28
Study 28075422 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month physical exercise program (5 days/week during RT, then 3 days/week)
Number of subjects: 72
Study 28075422 — intervention group
Group type: COMPARATOR
Intervention: Usual care according to recommendations
Number of subjects: 72
Study 26278231 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended-release (#300 mg per day) for 12-14 weeks
Number of subjects: 459
Study 23881815 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled reperfusion (CR)
Number of subjects: 174
Study 23881815 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT)
Number of subjects: 174
Study 23881815 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-protocol population with unilateral ischemia
Number of subjects: 174
Study 21654269 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg/d
Number of subjects: 0
Study 21654269 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 60 mg/d
Number of subjects: 0
Study 21654269 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 300 mg/d
Number of subjects: 0
Study 19781407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
Number of subjects: 1600
Study 19781407 — intervention group
Group type: COMPARATOR
Intervention: Standard statin therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins)
Number of subjects: 1600
Study 16721321 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (10‐50 mg/day)
Number of subjects: 206
Study 16721321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 16721321 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 206
Study 15301616 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbed visuomotor coupling during drawing task
Number of subjects: 0
Study 15301616 — intervention group
Group type: EXPERIMENTAL
Intervention: Figural discrepancies as additional cues
Number of subjects: 0
Study 11775645 — intervention group
Group type: EXPERIMENTAL
Intervention: Essaven gel (EG) - single acute application
Number of subjects: 10
Study 11775645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9623425 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% S(‐)‐bupivacaine
Number of subjects: 88
Study 9623425 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% S(‐)‐bupivacaine
Number of subjects: 88
Study 9623425 — intervention group
Group type: COMPARATOR
Intervention: 0.5% RS‐bupivacaine
Number of subjects: 88
Study 7919329 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL‐3 (2.5 or 5.0 micrograms/kg/day) administered by subcutaneous injection for either 5 or 10 days starting 4 hours after the marrow infusion followed by rhGM‐CSF (250 micrograms/m2/d as a 2‐hour intravenous infusion) until ANC > or = 1,500/microL for 3 consecutive days or until day 27 posttransplant.
Number of subjects: 37
Study 7919329 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF (250 micrograms/m2/d as a 2‐hour intravenous infusion) administered after rhIL‐3.
Number of subjects: 37
Study 3260866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 8
Study 3260866 — intervention group
Group type: COMPARATOR
Intervention: Placebo (plain water)
Number of subjects: 8
Study 30054842 — intervention group
Group type: EXPERIMENTAL
Intervention: CEGP-003 spray
Number of subjects: 72
Study 30054842 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine injection
Number of subjects: 72
Study 26262896 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day of algal DHA
Number of subjects: 730
Study 26262896 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 730
Study 24172538 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy pressure support ventilation (PSV)
Number of subjects: 13
Study 24172538 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure support ventilation (PSV)
Number of subjects: 13
Study 21178599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 39
Study 21178599 — intervention group
Group type: COMPARATOR
Intervention: Control (nonhypnotic relaxation)
Number of subjects: 39
Study 18311747 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurora kinase B expression
Number of subjects: 107
Study 18311747 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic instability related to Aurora kinase B expression
Number of subjects: 107
Study 16546105 — intervention group
Group type: EXPERIMENTAL
Intervention: MMC, 0.2 mg/ml applied for three minutes (Group 1)
Number of subjects: 120
Study 16546105 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autografting alone (Group 2)
Number of subjects: 120
Study 16546105 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride 0.9% only (Group 3)
Number of subjects: 120
Study 16546105 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival autografting combined with one minute application of MMC, 0.2 mg/ml (Group 4)
Number of subjects: 120
Study 12403254 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 12403254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10660096 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 800 mg/day for 12 weeks
Number of subjects: 0
Study 10660096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8570427 — intervention group
Group type: EXPERIMENTAL
Intervention: Canola oil cookies
Number of subjects: 0
Study 8570427 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut oil cookies
Number of subjects: 0
Study 2179650 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback to physicians of SDS scores of previously unrecognized depressed patients
Number of subjects: 100
Study 380253 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (0.5 g x 4 for 3 days)
Number of subjects: 30
Study 380253 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (0.5 g x 4 for 3 days)
Number of subjects: 30
Study 380253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 380253 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Paracetamol, Acetylsalicylic acid, Placebo)
Number of subjects: 30
Study 6578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 6578865 — intervention group
Group type: COMPARATOR
Intervention: Fluphenazine
Number of subjects: 0
Study 6578865 — intervention group
Group type: COMPARATOR
Intervention: Trifluoperazine
Number of subjects: 0
Study 6578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 6578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 0
Study 6578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 0
Study 6578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 30829734 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous preperitoneal wound infiltration (PPB)
Number of subjects: 40
Study 30829734 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia (EDB)
Number of subjects: 40
Study 30404139 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest model using NDVI series from the 120th to the 210th day in a year with 10 days' interval as predictors for maize yield estimation
Number of subjects: 0
Study 30404139 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forest model using a combination of three NDVI characteristics, three phenological characteristics, and two curve parameters as predictors for sunflower yield estimation
Number of subjects: 0
Study 30404139 — intervention group
Group type: EXPERIMENTAL
Intervention: NDVI series 50 days before crop harvest for both maize and sunflower
Number of subjects: 0
Study 27067129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psychosis (younger and older)
Number of subjects: 224
Study 27067129 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients with psychosis
Number of subjects: 224
Study 27067129 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with psychosis
Number of subjects: 224
Study 27067129 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients with psychosis
Number of subjects: 224
Study 25124683 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 41
Study 25124683 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion XL
Number of subjects: 41
Study 22238353 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR treatment for 48 months
Number of subjects: 27
Study 22238353 — intervention group
Group type: COMPARATOR
Intervention: Inactive group after treatment
Number of subjects: 27
Study 22238353 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with homeostasis model of assessment‐insulin resistance
Number of subjects: 27
Study 22238353 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with growth hormone (GH)
Number of subjects: 27
Study 20846991 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10001
Study 20846991 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 10001
Study 20846991 — intervention group
Group type: EXPERIMENTAL
Intervention: Low BP (<110‐120/<60‐70 mmHg)
Number of subjects: 10001
Study 18094424 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g daily for 3 days)
Number of subjects: 120
Study 18094424 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose (control)
Number of subjects: 120